A client with bipolar disorder, having experienced a depressive episode, is prescribed lamotrigine (Lamictal). After educating the client on this medication, the nurse determines that the education was successful when the client makes which statement?

Choice A reason: Lamotrigine does not require monthly blood tests, as it has minimal hematologic or hepatic toxicity. It stabilizes mood via sodium channel inhibition, with skin rash (e.g., Stevens-Johnson syndrome) being the primary concern, not routine blood monitoring. Choice B reason: Lamotrigine rarely affects liver function, unlike valproic acid. Its primary risk is cutaneous reactions due to immune-mediated hypersensitivity, not hepatotoxicity. Monitoring focuses on skin, not liver enzymes, as it modulates neuronal excitability without significant hepatic metabolism. Choice C reason: Lamotrigine carries a risk of serious skin rashes, like Stevens-Johnson syndrome, due to immune-mediated hypersensitivity affecting epidermal cells. Notifying the provider about rashes is critical, as this reflects understanding of the drug’s most significant adverse effect, ensuring timely intervention. Choice D reason: Salt intake is relevant for lithium, not lamotrigine, which stabilizes mood via sodium channel inhibition without affecting renal sodium handling. Dietary salt monitoring is unnecessary, as lamotrigine’s primary risk is dermatologic, not electrolyte-related, making this statement incorrect.